Fig. 3.

Effect of radiation when combined with intravascular or CED administration of nanoliposomal irinotecan therapy. Radiation treatment for this experiment was 1.5 Gy/day x 5, beginning day 7 and ending day 11, for a total radiation dose of 7.5 Gy. Nanoliposomal irinotecan administration was 0.4 mg on day 7 for CED administration and was 0.4 mg on days 7 and 11 for intravascular administration. (A) Treatment group day 10 bioluminescence distributions (last imaging day at which all control group mice were alive). See Table 3 for all 2-way comparisons using the Student's t-test. (B) Corresponding survival plots for all treatment groups. Log rank P values for all 2-way comparisons are listed in Table 4 and show that CED administration of irinotecan as a monotherapy was significantly better than intravascular and RT monotherapies and that RT + CED of irinotecan was significantly better than all other therapies, including irinotecan monotherapy via CED. The experiment was terminated at 70 days, at which time there was no detectable bioluminescence signal in surviving mice. Ten mice included in the survival analysis for all treatment groups.